Hill Catherine, Nicot Philippe, Piette Christine, Le Gleut Karelle, Durand Gérard, Toussaint Bruno
Institut Gustave Roussy, Villejuif, France.
Pharmacoepidemiol Drug Saf. 2015 May;24(5):543-7. doi: 10.1002/pds.3771. Epub 2015 Mar 31.
The aim of this study was to estimate of the number of sudden cardiac deaths attributable to the use of domperidone in France in 2012 METHODS: Computation of the attributable fraction, function of the increase in risk of sudden cardiac death induced by domperidone and of the exposure prevalence. Multiplying the attributable fraction by the risk of sudden cardiac death in the French population gives an estimation of the number of sudden cardiac deaths attributable to domperidone.
The use of domperidone in France is the cause of 231 deaths per year in the population aged 18 years or over.
This risk should be taken into consideration by clinicians when prescribing a drug which provides a minor benefit.
本研究旨在估算2012年在法国因使用多潘立酮导致的心源性猝死人数。方法：计算归因分数，该分数是多潘立酮诱发心源性猝死风险增加量及暴露患病率的函数。将归因分数乘以法国人群中心源性猝死风险，即可估算出因多潘立酮导致的心源性猝死人数。结果：在法国，18岁及以上人群中，每年有231例死亡是由使用多潘立酮引起的。结论：临床医生在开具益处较小的药物处方时，应考虑到这种风险。
